Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall ...
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session after the company reported weak fourth-quarter results, with revenue falling below Wall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback